“After the minimally invasive products, I am seeing a lot of reference to morphogenic proteins and note that generally more biologics are hitting the market ... “

— Pat Beyer of Stryker, commenting on a trend in the orthopedics sector, “New wave of CE-marked spine products shown at EuroSpine,” pp. 1, 7, 8.